emil
von
behr
shibasaburo
kitasato
work
robert
koch
laboratori
berlin
germani
initi
report
inject
toxin
diphtheria
tetanu
bacilli
led
anim
produc
blood
substanc
capabl
neutral
toxin
furthermor
inject
blood
serum
anim
given
chanc
develop
antitoxin
tetanu
diphtheria
could
confer
immun
diseas
anim
even
cure
anim
alreadi
sick
von
behr
conclud
immun
confer
protect
substanc
blood
call
antitoxin
substanc
specif
protect
one
particular
diseas
winau
et
al
period
robert
koch
laboratori
paul
ehrlich
show
acquir
immun
mice
transfer
offspr
mother
suppli
antibodi
fetu
circul
neonat
colostrum
silverstein
first
use
term
one
articl
defin
differ
activ
passiv
immun
suggest
koch
behr
ehrlich
work
optim
largescal
product
diphtheria
antitoxin
human
use
clinic
test
diphtheria
serum
earli
success
august
chemic
compani
hoechst
start
market
diphtheria
remedi
synthes
behringehrlich
paul
ehrlich
start
develop
imagin
idea
possibl
find
chemic
target
kill
diseasecaus
organ
leav
normal
bodi
cell
unharm
name
magic
bullet
use
term
first
describ
antibodi
later
chemic
bind
specif
kill
microb
tumor
cell
von
behr
first
nobel
prize
physiolog
medicin
work
serum
therapi
ehrlich
receiv
nobel
prize
togeth
eli
metschnikoff
sidechain
theori
chemic
theori
explain
format
antibodi
circul
cell
work
led
develop
theori
humor
immun
open
door
specif
treatment
infect
use
antisera
antibodi
serum
therapi
larg
use
begin
centuri
abandon
owe
hypersensit
reaction
introduct
antibiot
second
half
twentieth
centuri
inabl
treat
certain
viral
diseas
develop
antibiot
resist
bacteria
drove
effort
develop
antibodi
prepar
suitabl
oral
system
administr
casadeval
good
lorenz
develop
hybridoma
technolog
product
monoclon
antibodi
mab
provid
mean
produc
larg
amount
antibodi
one
specif
isotyp
kohler
milstein
technolog
advanc
chimer
human
mab
dna
shuffl
phage
display
technolog
led
gener
antibodi
antibodi
fragment
scfv
fab
fragment
improv
effici
reduc
immunogen
chan
et
al
new
method
product
antibodi
develop
includ
recombin
bacteria
insect
cell
transgen
plant
transgen
anim
discoveri
camelida
heavi
chain
antibodi
lack
light
chain
result
develop
singl
domain
antibodi
fragment
nanobodi
technolog
hamerscasterman
et
al
meanwhil
new
gener
receptor
protein
deriv
small
robust
nonimmunoglobulin
scaffold
born
binz
et
al
vast
major
infecti
agent
invad
human
bodi
epitheli
barrier
gastrointestin
genitourinari
respiratori
tract
mucos
immun
system
respond
produc
larg
amount
immunoglobulin
mucos
secret
act
first
line
defens
pathogen
human
secretori
iga
siga
repres
abund
immunoglobulin
bodi
secret
saliva
tear
colostrum
gastrointestin
togeth
varieti
innat
mucos
defens
mechan
function
secretori
antibodi
perform
immun
exclus
exogen
antigen
brandtzaeg
pathogen
cross
epithelium
invad
bodi
local
produc
antibodi
longer
determin
fate
host
system
immun
take
serum
immunoglobulin
particularli
immunoglobulin
ig
g
function
second
line
defens
elimin
pathogen
breach
mucos
barrier
patient
primari
immunodefici
involv
iga
known
highli
suscept
respiratori
gastrointestin
tract
infect
support
notion
crucial
role
antibodi
mucos
defens
suggest
use
role
passiv
immun
manag
mucos
infect
weiner
et
al
antibodi
bind
antigen
may
mediat
variou
differ
biolog
effect
casadeval
et
al
bacteri
infect
block
adhesin
promot
agglutin
neutral
enzym
activ
toxin
facilit
opson
togeth
complement
promot
bacteriolysi
viral
diseas
antibodi
block
viral
entri
uninfect
cell
promot
antibodydirect
cellmedi
cytotox
natur
killer
cell
neutral
viru
directli
particip
complement
matern
passiv
immun
type
natur
acquir
passiv
immun
refer
antibodymedi
immun
transfer
matern
antibodi
mother
fetu
newborn
essenti
develop
immun
system
protect
young
anim
variou
pathogen
earli
live
transfer
passiv
immun
mother
young
featur
order
mammal
gener
occur
transfer
matern
serum
igg
mother
offspr
either
utero
birth
ingest
immunoglobulinrich
colostrum
neonat
pathway
transfer
passiv
immun
vari
differ
anim
matern
igg
transfer
mainli
placenta
birth
guinea
pig
rabbit
nonhuman
primat
human
wherea
rumin
sheep
cattl
goat
hors
pig
newborn
born
agammaglobulinem
receiv
matern
antibodi
exclus
colostrum
lu
et
al
rodent
cat
dog
matern
antibodi
transport
offspr
antenat
neonat
pivot
molecul
respons
transfer
matern
igg
mammal
neonat
fc
receptor
fcrn
see
also
chapter
neonat
fc
receptor
major
histocompat
complex
class
irel
molecul
consist
first
identifi
protein
mediat
transfer
matern
milkborn
igg
across
neonat
rodent
intestin
gheti
ward
jakoi
et
al
studi
reveal
similar
receptor
human
found
facilit
transport
matern
igg
grow
fetu
leach
et
al
fcrn
sinc
identifi
mammal
includ
nonhuman
primat
spiekermann
et
al
rumin
sheep
cow
mayer
et
al
mayer
et
al
neonat
fc
receptor
also
mediat
transport
igg
multipl
mucos
barrier
protect
igg
albumin
intracellular
catabol
degrad
thu
extend
halfliv
bird
matern
igi
homolog
igg
transfer
across
yolk
sac
immun
chick
passiv
gestat
earli
life
chicken
yolk
sac
igi
receptor
fcri
ortholog
mammalian
phospholipas
receptor
mannos
receptor
famili
member
rather
fcrn
major
histocompat
complex
homolog
west
et
al
human
main
role
colostrum
consumpt
provid
protect
gastrointestin
tract
igg
requir
provid
system
immun
transfer
across
placenta
birth
probabl
explain
high
proport
siga
low
proport
igg
human
colostrum
milk
immunoglobulin
antibodi
breast
milk
reflect
antigen
stimul
gutassoci
lymphoid
tissu
nasopharynxassoci
lymphoid
tissu
tonsil
breast
milk
thu
contain
antibodi
direct
infecti
agent
exogen
antigen
mother
environ
like
encount
infant
human
breast
milk
may
contain
siga
antibodi
varieti
infecti
agent
vibrio
cholera
campylobact
jejuni
escherichia
coli
etec
shigella
salmonella
rotaviru
protect
infect
child
develop
diarrhea
lawrenc
pane
anim
content
ig
colostrum
milk
highli
depend
speci
hurley
theil
ungul
speci
cattl
sheep
goat
pig
young
born
essenti
agammaglobulinem
reli
entir
uptak
colostr
ig
especi
igg
system
immun
protect
colostr
igg
content
speci
typic
greater
total
ig
content
total
amount
ig
may
also
differ
colostrum
milk
bovin
colostrum
contain
level
ig
much
higher
sever
ordinari
bovin
milk
hurley
theil
immunoglobulin
found
mammari
secret
aris
system
local
sourc
case
igg
milk
major
portion
come
serum
enter
via
select
receptormedi
intracellular
rout
receptor
fcrn
surfac
epitheli
cell
mayer
et
al
uptak
milkderiv
igg
intestin
also
vari
speci
rat
mice
fcrnmediat
uptak
igg
colostrum
milk
neonat
intestin
newborn
artiodactyl
protein
includ
igg
nonselect
absorb
first
h
birth
abil
enterocyt
pinocyt
transport
igg
lost
h
quigley
macromolecul
transport
releas
lamina
propria
absorb
lymphat
portal
circul
vaccin
natur
immun
pregnant
cow
ewe
sow
enterotoxigen
e
coli
intestin
virus
provid
degre
protect
newborn
hurley
theil
neonat
calv
piglet
matern
ig
transfer
respiratori
tract
secret
contribut
local
protect
infect
caus
virus
includ
bovin
respiratori
syncyti
viru
rsv
porcin
respiratori
coronaviru
belknap
et
al
sestak
et
al
result
transfer
antibodi
crucial
understand
passiv
immun
pathogen
develop
passiv
immunotherapi
manag
infect
unlik
activ
immun
take
day
week
develop
passiv
administ
antibodi
abil
provid
rapid
immedi
protect
exampl
agent
bioterror
casadeval
et
al
unlik
vaccin
protect
immun
depend
host
abil
mount
immun
respons
passiv
antibodi
independ
recipi
immun
statu
passiv
immun
may
thu
repres
therapi
choic
highli
endem
area
vaccin
respons
may
poor
select
group
patient
hospit
individu
suffer
malnutrit
immunodefici
individu
vaccin
contraind
howev
protect
confer
passiv
immun
short
durat
might
need
repeat
administr
furthermor
given
mucos
surfac
oral
deliveri
antibodi
may
degrad
gastric
acid
proteolyt
enzym
product
purif
larg
amount
antibodi
thu
result
high
cost
anoth
disadvantag
mab
emerg
variant
lack
determin
antibodi
recogn
viral
escap
mutant
recent
research
make
use
technolog
engin
resist
antibodi
react
multipl
epitop
choic
antibodi
use
therapi
infecti
agent
may
depend
rout
administr
statu
host
microorgan
target
econom
factor
variou
antibodi
isotyp
may
confer
differ
biolog
properti
antibodi
molecul
certain
class
ig
iga
appear
resist
proteolyt
degrad
class
therefor
advantag
oral
administr
wherea
erad
infect
may
requir
full
antibodi
mediat
phagocytosi
complement
activ
antibodydepend
cellular
cytotox
antibodi
fragment
may
suffici
neutral
toxin
viru
immunoglobulin
antibodi
fragment
interact
host
immun
system
might
also
desir
protect
mucos
surfac
promot
immun
exclus
without
induc
inflamm
furthermor
human
mab
appropri
intraven
administr
polyclon
antibodi
less
like
transmit
infecti
diseas
caus
toxic
howev
polyclon
antibodi
prepar
usual
less
costli
produc
may
better
choic
oral
administr
protect
certain
infect
reduct
sever
ill
caus
achiev
administ
polyclon
antibodi
deriv
human
anim
serum
prepar
avail
may
standard
ig
human
origin
sometim
refer
immun
serum
globulin
gammaglobulin
special
prepar
either
human
anim
sera
contain
high
titer
specif
antibodi
particular
microorgan
toxin
orang
et
al
product
human
origin
prefer
anim
origin
high
incid
advers
reaction
anim
sera
longerlast
protect
confer
human
ig
immunoglobulin
often
refer
gammaglobulin
produc
combin
igg
antibodi
fraction
thousand
adult
donor
base
assumpt
larg
pool
contain
protect
level
antibodi
differ
specif
includ
antibodi
mani
common
diseas
hepat
measl
rubella
ig
product
steril
contain
purifi
igg
small
amount
iga
igm
use
primarili
postexposur
prophylaxi
hepat
rubella
measl
treatment
certain
primari
immunodefici
disord
xlink
hypogammaglobulinemia
secondari
immunodefici
bcell
chronic
lymphocyt
leukemia
autoimmun
diseas
histor
ig
given
subcutan
intramuscularli
igg
prepar
contain
aggreg
igg
impur
often
caus
seriou
reaction
administ
intraven
today
intraven
ig
ivig
subcutan
ig
scig
replac
therapi
gener
accept
treatment
select
patient
immunodefici
current
accept
therapi
igg
defici
intraven
administr
mgkg
igg
everi
week
mgkg
week
subcutan
orang
et
al
immunoglobulin
therapi
given
intraven
subcutan
rout
equal
efficaci
infect
reduct
gardulf
et
al
chapel
et
al
decreas
frequenc
sever
otiti
respiratori
tract
infect
stiehm
et
al
human
hyperimmuneglobulin
made
donat
plasma
human
high
level
antibodi
interest
prepar
ig
harvest
select
individu
donor
either
recent
recov
diseas
deliber
immun
hyperimmuneglobulin
use
postexposur
prophylaxi
sever
diseas
includ
hepat
b
rabi
tetanu
cytomegaloviru
varicella
stiehm
et
al
heterolog
hyperimmun
serum
produc
anim
usual
hors
equin
toxin
clostridium
botulinum
clostridium
tetani
corynebacterium
diphtheria
casadeval
et
al
problem
product
serum
sick
immun
reaction
hors
protein
number
advantag
use
cow
chicken
product
antibodi
bovin
colostrum
igi
product
less
invas
requir
collect
egg
milk
compar
blood
collect
mammal
repres
rel
inexpens
sourc
antibodi
colostrum
immun
anim
may
increas
antibodi
titer
compar
colostrum
nonimmun
anim
janson
et
al
colostrum
contain
mg
immunoglobulin
per
millilit
berghman
et
al
cow
produc
kg
immunoglobulin
first
day
calv
thu
attract
largescal
antibodi
product
immun
protocol
vari
gener
repeat
immun
administ
late
pregnanc
dri
period
mani
studi
use
intramuscular
subcutan
immun
although
also
incorpor
oral
intramammari
immun
less
success
mammari
secret
collect
either
first
milk
pool
first
four
six
milk
first
six
day
calv
hurley
theil
immun
chicken
requir
small
amount
antigen
obtain
high
longlast
igi
titer
egg
yolk
tini
et
al
common
inject
rout
intramuscular
result
higher
level
specif
igi
antibodi
subcutan
immun
chang
et
al
concentr
igi
egg
yolk
reach
mgml
hen
lay
egg
year
yield
hyperimmun
igi
could
larg
mg
igi
could
obtain
singl
egg
one
immun
hen
could
produc
g
igi
year
expect
antigenspecif
hatta
et
al
contrast
mammalian
serum
egg
yolk
contain
singl
class
antibodi
igi
easili
isol
yolk
precipit
techniqu
igi
activ
mammalian
complement
interact
mammalian
fc
receptor
could
mediat
inflammatori
respons
kovacsnolan
mine
resist
bovin
igi
low
ph
lumin
proteolysi
make
function
similar
human
iga
suitabl
oral
administr
kovacsnolan
mine
rumin
transmit
matern
immun
postnat
colostr
antibodi
quigley
colostrum
egg
yolk
antibodi
routin
use
prophylaxi
therapi
infecti
diseas
farm
anim
berghman
et
al
bovin
immunoglobulin
prepar
rotaviru
e
coli
etec
commerci
avail
use
farm
anim
decad
owe
low
cost
easi
administr
high
number
control
clinic
studi
use
hyperimmun
bovin
colostrum
egg
yolk
antibodi
shown
prophylact
therapeut
effect
oral
gastrointestin
pathogen
human
includ
enterotoxicogen
e
coli
helicobact
pylori
dental
cari
caus
streptococcu
mutan
rotavir
infect
hurley
theil
kovacsnolan
mine
weiner
et
al
abil
bovin
egg
yolk
antibodi
provid
protect
specif
diseas
continu
area
interest
ng
et
al
exampl
bovin
igg
reactiv
abl
neutral
human
immunodefici
viru
hiv
develop
potenti
efficaci
afford
topic
microbicid
kramski
et
al
first
gener
mab
produc
singl
hybridoma
clone
obtain
fusion
myeloma
cell
plasma
cell
immun
mous
use
therapeut
mab
anim
origin
compromis
immunolog
respons
mab
creation
chimer
mab
compos
human
constant
domain
c
h
c
l
rodent
variabl
domain
v
h
v
l
led
reduct
human
antichimer
antibodi
respons
human
mab
consist
cdr
rodent
mab
clone
framework
region
human
mab
reduc
immunogen
much
expect
chan
et
al
furthermor
human
often
accompani
loss
affin
residu
framework
region
need
backmut
achiev
accept
affin
circumv
immunogen
issu
full
human
mab
gener
transgen
mice
chan
et
al
lonberg
reli
gener
transgen
mice
murin
immunoglobulin
gene
disrupt
replac
human
ig
gene
cluster
transgen
mice
produc
human
antibodi
respons
immun
antigen
clone
isol
hybridoma
technolog
phage
antibodi
librari
nearli
therapeut
mab
approv
food
drug
administr
market
unit
state
today
zhang
origin
hybridoma
fulllength
antibodi
molecular
format
includ
murin
chimer
human
human
antibodi
categori
one
mab
palivizumab
human
mab
licens
infecti
diseas
respiratori
syncyti
viru
infect
buss
et
al
huang
et
al
monoclon
ab
hiv
viral
hepat
rabi
clostridium
difficil
toxin
pseudomona
aeruginosa
clinic
develop
buss
et
al
nelson
et
al
raxibacumab
human
mab
protect
antigen
pa
bacillu
anthraci
significantli
increas
surviv
monkey
vs
placebo
inhal
anthrax
spore
migon
et
al
licens
resubmit
contain
addit
valid
previou
data
evalu
potenti
ad
benefit
use
raxibacumab
antibiot
versu
antibiot
alon
limit
hybridoma
technolog
advanc
molecular
biolog
led
sever
research
group
investig
product
antibodi
recombin
form
full
antibodi
easili
express
bacteria
owe
impair
fold
technolog
antigenbind
part
antibodi
molecul
fab
fv
fragment
express
e
coli
introduc
skerra
pluckthun
later
shown
scfv
fragment
display
phage
surfac
function
protein
retain
activ
antigenbind
domain
capabl
finlay
et
al
past
decad
phage
display
techniqu
routin
use
gener
select
scfv
fab
singl
v
l
v
h
domain
deriv
convent
antibodi
variabl
domain
camelida
heavi
chain
antibodi
vhh
figur
grow
interest
produc
new
format
antibodi
tailor
desir
produc
larg
quantiti
employ
bacteri
yeast
cultur
singl
chain
fragment
variabl
scfv
kda
consist
variabl
region
heavi
v
h
light
v
l
chain
join
togeth
flexibl
peptid
linker
scfv
order
domain
either
v
h
linkerv
l
v
l
linkerv
h
orient
peptid
linker
usual
linker
sequenc
gli
ser
finlay
et
al
larger
fab
heterodim
consist
variabl
first
constant
domain
heavi
v
h
c
h
light
chain
v
l
c
l
segment
link
disulfid
bond
fragment
show
similar
bind
specif
origin
antibodi
low
degre
immunogen
easili
manipul
bival
parent
antibodi
smaller
size
fragment
permit
penetr
tissu
inaccess
fullsiz
mab
yokota
et
al
downsid
fragment
demonstr
short
circul
halfliv
human
like
owe
kidney
clearanc
fab
fv
fragment
success
gener
hybridoma
cell
kruger
et
al
howev
select
antibodi
fragment
differ
specif
high
bind
affin
gener
prefer
select
fragment
directli
phage
librari
select
scfv
fab
v
h
v
l
directli
use
fragment
reconvert
differ
antibodi
format
fulllength
antibodi
minibodi
scfvfc
diabodi
among
other
hollig
hudson
nelson
et
al
figur
phage
display
technolog
use
gener
least
fulllength
human
antibodi
clinic
develop
includ
influenza
viru
ps
aeruginosa
nelson
et
al
member
camelida
famili
ie
camelu
dromedariu
camelu
bactrianu
lama
glama
lama
guanaco
lama
alpaca
lama
vicugna
produc
heavi
chainonli
antibodi
hcab
type
antibodi
lack
first
constant
domain
chapter
light
chain
hamerscasterman
et
al
rahbarizadeh
et
al
antigenbind
fragment
hcab
compos
singledomain
refer
vhh
variabl
domain
llama
heavi
chain
antibodi
nanobodi
camelida
heavi
chain
antibodi
small
kda
stabl
molecul
superior
solubl
similar
affin
convent
antibodi
harmsen
de
haard
camelida
heavi
chain
antibodi
exhibit
sever
advantag
convent
antibodi
deriv
fragment
markedli
acidand
heatresist
convent
antibodi
form
singl
polypeptid
easier
express
function
recombin
form
harmsen
de
haard
vanlandschoot
et
al
properti
make
suitabl
therapi
mucos
site
gastrointestin
tract
acid
ph
limit
function
figur
schemat
represent
antibodi
antibodi
fragment
convent
antibodi
contain
two
variabl
region
compos
v
h
v
l
domain
confer
antigenbind
specif
antibodi
fc
fragment
constant
region
recruit
effect
function
immun
system
camelida
heavi
chain
antibodi
lack
constant
variabl
light
chain
c
l
v
l
first
heavi
chain
constant
c
h
domain
antigenbind
site
form
heavi
chain
variabl
domain
v
h
h
nanobodi
convent
antibodi
addit
owe
small
size
natur
longer
region
llama
vhh
antibodi
fragment
superior
convent
antibodi
access
cleft
activ
site
enzym
canyon
viru
capsid
lauwerey
et
al
small
size
also
allow
penetr
tissu
tumor
rapidli
deepli
mab
camelida
heavi
chain
antibodi
low
immunogen
unlik
exhibit
untoward
side
effect
chronic
applic
coppiet
et
al
moreov
camel
milk
contain
heavi
chain
antibodi
regularli
consum
africanarab
countri
without
advers
effect
camelida
heavi
chain
antibodi
usual
gener
polymeras
chain
reaction
clone
variabl
domain
repertoir
blood
lymph
node
spleen
cdna
obtain
immun
anim
phage
display
vector
largescal
product
vhh
yeast
saccharomyc
cerevisia
highli
effici
result
secret
function
antibodi
fragment
vhh
growth
medium
frenken
et
al
sever
vhh
current
studi
use
variou
area
includ
infecti
diseas
harmsen
de
haard
camelida
heavi
chain
antibodi
gener
protozoa
trypanosoma
evansi
bacteria
str
mutan
cl
difficil
cl
botulinum
virus
respiratori
syncyti
viru
rotaviru
rabi
viru
influenza
hiv
rahbarizadeh
et
al
vanlandschoot
et
al
camelida
heavi
chain
antibodi
rsv
rotaviru
clinic
develop
oral
consumpt
vhh
rotaviru
also
confirm
safe
human
safeti
studi
sarker
et
al
small
size
gene
domain
strict
monomer
solubl
behavior
render
vhh
ideal
gener
multival
multispecif
construct
integr
complex
assembl
fuse
fc
enzym
toxin
bival
bispecif
vhh
construct
assembl
target
multipl
antigen
epitop
cell
antigen
greatli
improv
neutral
potenc
reduc
risk
escap
mutant
emerg
protein
engin
techniqu
new
bind
protein
base
altern
scaffold
design
therapeut
agent
new
scaffold
protein
attract
physic
chemic
properti
convent
antibodi
higher
solubl
affin
stabil
absenc
disulfid
bridg
optim
express
microorgan
divers
potenti
applic
led
investig
scaffold
includ
affibodi
fibronectin
darpin
variabl
lymphocyt
receptor
vlr
lamprey
among
other
alder
et
al
boersma
pluckthun
hackel
et
al
nygren
tasumi
et
al
confer
effector
function
protein
one
also
fuse
scaffold
fc
region
antibodi
sever
altern
bind
protein
preclin
investig
data
exist
serum
halflif
tissu
penetr
immunogen
altern
bind
molecul
sever
express
system
avail
product
antibodi
antibodi
fragment
includ
bacteria
yeast
plant
insect
mammalian
cell
well
transgen
anim
schirrmann
et
al
mammalian
cell
cultur
predominantli
chines
hamster
ovari
cell
murin
myeloma
cell
line
nso
domin
product
platform
therapeut
mab
wherea
yeast
gener
use
vhh
fragment
need
develop
technolog
produc
antibodi
lower
cost
although
tobacco
use
earli
studi
hiatt
et
al
larg
number
differ
crop
use
produc
antibodi
antibodi
fragment
includ
cereal
legum
fruit
schirrmann
et
al
see
also
chapter
plantibodi
combat
infecti
diseas
includ
siga
recogn
surfac
antigen
iii
str
mutan
protect
cari
produc
tobacco
human
antibodi
produc
tobacco
human
mab
produc
maiz
use
topic
microbicid
prevent
hiv
infect
vhh
fragment
rotaviru
produc
rice
tokuhara
et
al
yusibov
et
al
plant
bioreactor
expect
yield
kg
therapeut
antibodi
per
acr
tobacco
maiz
soybean
alfalfa
cost
least
time
less
compar
steeltank
bioreactor
use
mammalian
cell
microorgan
larrick
thoma
antibodycontain
cereal
rice
wheat
pea
seed
store
room
temperatur
major
advantag
use
develop
countri
use
transgen
farm
anim
product
mab
milk
egg
yolk
investig
previous
castilla
et
al
demain
vaishnav
houdebin
kawab
et
al
lillico
et
al
pollock
et
al
zhu
et
al
advantag
transgen
anim
antibodi
product
would
low
cost
product
well
high
qualiti
protein
farm
anim
could
also
use
product
polyclon
human
antibodi
houdebin
transgen
cattl
gener
transfer
human
artifici
chromosom
vector
carri
entir
unrearrang
human
ig
heavi
high
higk
chain
loci
bovin
fibroblast
two
endogen
bovin
igh
chain
loci
inactiv
kuroiwa
et
al
product
human
antibodi
await
complet
inactiv
correspond
cow
ig
gene
similar
approach
also
current
perform
chicken
houdebin
lactobacilli
gramposit
bacteria
normal
resid
orogastrointestin
vagin
tract
also
use
food
ferment
preserv
gener
regard
safe
human
statu
led
report
lactobacilli
produc
antibodi
fragment
ie
lactobodi
either
secret
display
surfac
directli
use
oral
administr
treatment
mucos
infect
kruger
et
al
kruger
et
al
marcott
et
al
martin
et
al
pant
et
al
stabl
contain
express
system
develop
allow
transform
lactobacilli
administ
human
martin
et
al
antibodi
fragment
express
lactobacilli
isol
oral
gastrointestin
vagin
tract
protect
differ
mucos
surfac
use
genet
engin
antibodi
fragment
produc
local
deliv
bacteria
mucos
site
could
thu
provid
effici
therapi
low
cost
particularli
develop
countri
passiv
immun
use
year
variou
pathogen
anim
human
summar
publish
data
use
antibodi
prophylaxi
therapi
select
pathogen
infect
oral
pulmonari
gastrointestin
vagin
tract
tabl
also
want
highlight
protect
confer
differ
form
antibodi
develop
produc
deliv
use
differ
approach
technolog
streptococcu
mutan
normal
resid
human
oral
caviti
recogn
one
major
etiolog
agent
cari
passiv
immun
cari
develop
use
oral
administr
antibodi
prepar
whole
cell
str
mutan
associ
virul
factor
involv
bacteria
adher
tabl
oral
administr
hyperimmun
bovin
milk
chicken
antibodi
str
mutan
glucosyltransferas
result
reduct
str
mutan
dental
plaqu
cari
format
rat
reduc
count
str
mutan
saliva
dental
plaqu
human
filler
et
al
hamada
et
al
hatta
et
al
kruger
et
al
loimaranta
et
al
michalek
et
al
otak
et
al
antibodi
prepar
may
protect
str
mutan
differ
mechan
inhibit
format
extracellular
polysaccharid
glucan
fructan
prevent
adher
str
mutan
salivari
coat
hydroxyapatit
aggreg
str
mutan
loimaranta
et
al
loimaranta
et
al
anoth
approach
use
mab
cell
surfac
antigen
iii
saiii
adhes
molecul
str
mutan
lehner
et
al
et
al
et
al
et
al
human
volunt
receiv
treatment
consist
oral
chlorhexidin
disinfect
follow
repeat
topic
applic
antiagiii
mab
guy
onto
teeth
show
lack
recolon
indigen
str
mutan
year
et
al
et
al
function
mab
detect
teeth
day
applic
specul
ecolog
nich
vacat
str
mutan
fill
bacteria
et
al
mab
subsequ
reengin
chimer
igaigg
ab
rabbit
secretori
compon
express
tobacco
plant
plantderiv
sigag
carorx
planet
biotechnolog
report
effect
passiv
immun
trial
human
et
al
et
al
although
anoth
studi
report
trend
reduc
colon
str
mutan
weintraub
et
al
product
current
undergo
phase
ii
clinic
trial
unit
state
scfv
also
deriv
mab
guy
express
lactobacilli
kruger
et
al
administr
fresh
lactobacilli
express
surfac
anchor
scfv
drink
water
reduc
str
mutan
bacteri
count
cari
develop
rat
kruger
et
al
kruger
et
al
modifi
lactobacilli
could
prevent
cari
differ
mechan
block
saiii
adhes
aggreg
str
mutan
combin
product
inhibitori
substanc
eg
bacteriocin
kruger
et
al
vhh
antibodi
fragment
saiii
adhesin
also
reduc
develop
smooth
surfac
cari
desaliv
rat
cari
model
kruger
et
al
porphyromona
gingivali
gramneg
anaerob
present
subgingiv
plaqu
identifi
major
etiolog
agent
chronic
periodont
marcott
lavoi
factor
po
gingivali
might
express
virul
includ
lipopolysaccharid
hemagglutinin
fimbria
argxspecif
rgp
lysxspecif
kgp
cystein
proteinas
gingipain
andrian
et
al
immunoglobulin
po
gingivali
outer
membran
protein
hemagglutinin
haga
found
inhibit
aggreg
hemagglutin
vitro
hamajima
et
al
tezuka
et
al
egg
yolk
antibodi
po
gingivali
gingipain
decreas
bacteri
adhes
pachl
et
al
art
antiretrovir
therapi
hydrolyt
activ
vitro
yokoyama
et
al
reduc
level
po
gingivali
appli
teeth
periodont
patient
yokoyama
et
al
antipo
gingivali
mab
reactiv
adhesionassoci
epitop
contain
beta
fragment
gingipain
rgpa
shown
inhibit
hemagglutin
human
red
blood
cell
po
gingivali
booth
lehner
topic
applic
mab
patient
periodont
prevent
recolon
po
gingivali
month
booth
et
al
modifi
lactobacilli
express
scfv
deriv
cell
surfac
also
shown
aggreg
po
gingivali
inhibit
growth
vitro
oropharyng
candidiasi
mostli
associ
candida
albican
major
caus
morbid
immunocompromis
patient
hiv
organand
bone
marrowtranspl
patient
dongaribagtzogl
fidel
hung
et
al
narrow
rang
antifung
agent
toxic
drug
emerg
resist
strain
albican
highlight
need
new
therapeut
approach
invas
candidiasi
espinelingroff
antibodi
may
import
role
block
adhes
albican
tissu
inhibit
germ
tube
format
promot
phagocytosi
cabeza
et
al
coleman
et
al
de
bernardi
et
al
wellington
et
al
polyclon
igi
antibodi
prepar
albican
shown
prevent
growth
adher
epitheli
cell
biofilm
format
albican
vitro
fujibayashi
et
al
wang
et
al
reduc
oral
candidiasi
system
dissemin
administ
oral
immunosuppress
mice
ibrahim
et
al
antibodi
cow
immun
whole
candida
organ
purifi
mannan
prevent
adher
albican
oral
buccal
cell
dosedepend
manner
weiner
et
al
reduc
candida
count
saliva
administ
oral
bone
marrowtranspl
patient
tollemar
et
al
efungumab
mycograb
develop
human
recombin
scfv
antibodi
fragment
heat
shock
protein
treatment
invas
candida
infect
combin
amphotericin
b
matthew
burni
matthew
et
al
pachl
et
al
despit
efficaci
combin
treatment
anim
model
clinic
trial
mycograb
receiv
licensur
european
medicin
agenc
clinic
use
owe
safeti
concern
mainli
regard
autoaggreg
compound
novarti
ag
discontinu
develop
antibodi
despit
issu
efungumab
demonstr
import
proof
principl
develop
mab
antifung
activ
almost
patient
primari
antibodi
defici
pad
upper
lower
respiratori
tract
bacteri
infect
predominantli
otiti
media
sinus
pneumonia
lifethreaten
infect
pad
patient
caus
mainli
encapsul
bacteria
especi
streptococcu
pneumonia
haemophilu
influenza
type
b
hib
furthermor
infant
young
children
hib
caus
bacteremia
pneumonia
acut
bacteri
mening
past
year
sever
studi
demonstr
replac
ig
therapi
ivig
scig
benefici
pad
patient
bari
et
al
chapel
et
al
fri
bonilla
wood
swanson
tabl
furthermor
human
hyperimmunoglobulin
term
bacteri
polysaccharid
immun
globulin
bpig
prepar
plasma
donor
immun
hib
pneumococc
meningococc
capsular
ps
vaccin
product
administ
intramuscularli
protect
hib
bacteremia
mening
pneumococc
otiti
infant
santosham
et
al
shurin
et
al
siber
et
al
main
virul
factor
str
pneumonia
h
influenza
polysaccharid
ps
capsul
reflect
import
role
antibodi
opson
encapsul
bacteria
one
option
thu
develop
mab
target
capsular
polysaccharid
serotyp
caus
infect
give
mab
mixtur
intraperiton
administr
mab
capsular
polysaccharid
protect
mice
lethal
system
intranas
challeng
str
pneumonia
serotyp
iii
chang
et
al
fabrizio
et
al
b
tian
et
al
weber
et
al
protect
mab
promot
phagocytosi
vitro
efficaci
may
depend
capac
agglutin
alter
express
gene
involv
quorum
sens
trick
bacteria
kill
fratricid
fabrizio
et
al
tian
et
al
yano
et
al
gramneg
bacterium
ps
aeruginosa
opportunist
nosocomi
pathogen
immunocompromis
patient
major
caus
morbid
mortal
cystic
fibrosi
patient
mullerpremru
gubina
alreadi
intrins
resist
mani
antibiot
report
ps
aeruginosa
acquisit
multidrug
resist
lategener
antibiot
common
jovcic
et
al
administr
polyclon
antibodi
prepar
deriv
healthi
human
donor
immun
ps
aeruginosa
psivig
associ
greater
prolong
improv
pulmonari
function
patient
moder
cystic
fibrosi
cryz
et
al
potenti
mab
target
virul
factor
demonstr
anim
model
ps
aeruginosa
pneumonia
use
system
intratrach
administr
mab
target
ps
aeruginosa
oantigen
lipopolysaccharid
lp
flagella
algin
exopolysaccharid
compon
type
secret
system
pcrv
adawi
et
al
baer
et
al
digiandomenico
et
al
faur
et
al
horn
et
al
pier
et
al
secher
et
al
phase
iia
clinic
trial
infus
mab
panobacumab
kenta
biotech
switzerland
kalobio
pharmaceut
inc
us
target
oantigen
lp
pcrv
respect
support
use
passiv
immun
ps
aeruginosa
pneumonia
human
francoi
et
al
lu
et
al
furthermor
mouth
rins
contain
purifi
antip
aeruginosa
igi
given
twice
daili
continu
basi
could
significantli
reduc
prevent
ps
aeruginosa
colon
patient
cystic
fibrosi
nilsson
et
al
nilsson
et
al
igi
prepar
psaerigi
receiv
orphan
drug
design
european
medicin
agenc
emea
phase
iii
doubleblind
random
control
trial
way
influenza
type
virus
subdivid
subtyp
base
antigen
properti
two
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
daniel
et
al
multipl
clade
subclad
influenza
virus
high
mutat
rate
infect
constitut
consider
problem
human
vaccin
develop
stephenson
et
al
system
administr
polyclon
antibodi
influenza
viru
shown
protect
human
mous
model
infect
kong
zhou
lu
et
al
zhou
et
al
furthermor
singl
intranas
administr
igi
hyperimmun
bovin
colostrum
hbc
prophylact
therapeut
protect
intranas
challeng
influenza
viru
ng
et
al
nguyen
et
al
ha
protein
respons
receptor
bind
host
cell
viral
entri
elicit
robust
neutral
antibodi
vaccin
natur
infect
sever
group
report
system
intranas
administr
mab
ha
provid
protect
mice
lethal
intranas
challeng
viru
prabhu
et
al
tan
et
al
throsbi
et
al
ye
et
al
antigen
drift
caus
period
amino
acid
chang
globular
head
hemagglutinin
ha
one
hallmark
influenza
viru
immun
evas
synergist
action
two
mab
combin
may
requir
prevent
gener
escap
mutant
prabakaran
et
al
altern
develop
antibodi
target
conserv
region
ha
capabl
recogn
neutral
divers
number
influenza
viru
subtyp
ekiert
et
al
tan
et
al
broadli
neutral
mab
shown
bind
highli
conserv
helic
region
ha
stemstalk
domain
ekiert
et
al
throsbi
et
al
antibodi
develop
crucel
netherland
current
undergo
phase
clinic
trial
fuse
singl
intraven
dose
camelida
heavi
chain
antibodi
fragment
also
develop
multival
vhh
produc
genet
fusion
two
three
neutral
vhh
bival
vhh
least
effect
suppress
viru
replic
lung
monoval
counterpart
protect
mice
lethal
viru
challeng
prophylact
therapeut
set
crosslink
spike
subunit
multimer
vhh
may
increas
avid
mediat
agglutin
virus
inhibit
conform
chang
virus
therebi
prevent
fusion
host
cell
membran
respiratori
syncyti
viru
lead
viral
pathogen
respons
lower
respiratori
tract
infect
lrti
requir
hospit
infant
young
children
worldwid
respiratori
syncyti
viru
recent
found
high
preval
elderli
immunocompromis
adult
particularli
bone
marrow
lung
transplant
recipi
lead
consider
morbid
mortal
hynicka
ensor
two
glycosyl
surfac
protein
f
g
crucial
infect
pathogenesi
viru
elicit
product
neutral
antibodi
host
hall
lack
effect
therapi
vaccin
rsv
infect
led
studi
examin
effect
passiv
immun
princ
et
al
two
rsv
passiv
antibodi
prepar
origin
licens
respiratori
syncyti
virusigiv
hyperimmun
polyclon
human
igg
prepar
deriv
plasma
donor
high
rsv
neutral
antibodi
titer
approv
use
infant
children
younger
month
chronic
lung
diseas
histori
prematur
birth
palivizumab
synagi
medimmun
gaithersburg
md
human
mab
direct
antigen
site
ii
f
glycoprotein
block
viru
fusion
like
inhibit
conform
chang
f
protein
requir
process
huang
et
al
palivizumab
licens
reduct
sever
lower
respiratori
tract
rsv
infect
highrisk
infant
children
palivizumab
rsvigiv
similarli
decreas
incid
rsv
hospit
intens
care
unit
admiss
rsvigiv
result
advers
effect
requir
intraven
access
morri
et
al
palivizumab
might
also
viabl
option
prophylaxi
rsv
patient
undergo
allogen
stem
cell
transplant
preengraft
graftversushost
diseas
treat
highdos
steroid
kassi
et
al
vhh
antibodi
fragment
vhh
direct
antigen
site
ii
f
protein
compet
palivizumab
isol
remark
link
two
ident
vhh
improv
vitro
neutral
trival
molecul
consist
three
ident
antirsv
vhh
ablynx
also
construct
shown
protect
intranas
instil
cotton
rat
model
even
day
infect
wwwablynxcom
phase
studi
healthi
volunt
indic
could
success
administ
via
nebul
directli
lung
induc
signific
clinic
relev
advers
event
wwwablynxcom
helicobact
pylori
infect
respons
chronic
gastriti
peptic
ulcer
diseas
associ
increas
risk
develop
stomach
cancer
suerbaum
michetti
although
antimicrobi
therapi
avail
cost
antibiot
therapi
appear
antibiot
resist
suggest
effect
altern
prevent
strategi
would
great
benefit
particularli
develop
countri
promin
h
pylori
virul
factor
blood
group
antigenbind
adhesin
baba
babb
babc
sialic
acidbind
adhesin
saba
cytotoxinassoci
antigen
caga
vacuol
cytotoxin
vaca
ureas
involv
gastric
acid
neutral
backert
clyne
delay
acquisit
h
pylori
gambian
infant
correspond
mother
level
breast
milk
iga
specif
h
pylori
suggest
oral
administr
antibodi
might
use
prevent
reduc
infect
h
pylori
gorrel
robinsbrown
thoma
et
al
furthermor
mice
given
mous
mab
helicobact
virul
factor
ureas
time
initi
challeng
protect
infect
blanchard
et
al
czinn
et
al
tabl
antibodi
cow
chicken
immun
whole
cell
lysat
ureas
inhibit
adher
h
pylori
gastric
mucosa
growth
ureas
activ
vitro
casswal
et
al
shimamoto
et
al
shin
et
al
oral
administr
antibodi
prepar
also
reduc
colon
h
pylori
associ
gastriti
rodent
model
casswal
et
al
malekshahi
et
al
nomura
et
al
shimamoto
et
al
shin
et
al
howev
clinic
studi
effect
oral
administr
colostrum
antibodi
igi
antibodi
h
pylori
human
rare
show
contradictori
result
studi
thu
show
decreas
colon
symptom
ando
nakamura
casswal
et
al
tarpila
wherea
studi
shown
effect
colostrumderiv
antibodi
casswal
et
al
den
ho
et
al
opekun
et
al
moder
effect
antiureas
igi
hori
et
al
suzuki
et
al
antibodi
h
pylori
adhesin
develop
although
latter
identifi
well
character
aspholmhurtig
et
al
ilver
et
al
mahdavi
et
al
recent
scfv
antibodi
fragment
baba
adhesin
isol
phage
librari
deriv
pbmc
h
pylori
infect
human
schmidt
et
al
prepar
complet
human
antibodi
deriv
scfv
prevent
adher
h
pylori
stomach
section
rotaviru
import
etiolog
agent
sever
diarrhea
young
children
account
estim
death
year
mainli
develop
world
two
licens
vaccin
rotarix
rotateq
reduc
efficaci
develop
countri
africa
asia
armah
et
al
madhi
et
al
compar
develop
countri
ruizpalacio
et
al
vesikari
et
al
thu
need
altern
strategi
complement
vaccin
strategi
situat
efficaci
vaccin
alon
may
suffici
marcott
et
al
studi
human
mice
suggest
role
secretori
iga
serum
igg
antibodi
protect
rotaviru
coulson
et
al
istrat
et
al
velazquez
et
al
outer
capsid
protein
intermedi
layer
protein
like
import
target
host
neutral
respons
aladin
et
al
burn
et
al
corthesi
et
al
ruggeri
et
al
monoclon
ab
inhibit
infect
block
attach
ruggeri
greenberg
antibodi
inhibit
decapsid
aoki
et
al
antibodi
inhibit
genom
transcript
viral
transcript
vitro
feng
et
al
sever
studi
shown
passiv
immun
use
hyperimmun
polyclon
bovin
colostrum
hyperimmun
chicken
egg
yolk
ig
protect
anim
model
human
davidson
et
al
hammarstrom
weiner
pant
et
al
sarker
et
al
sarker
et
al
sarker
et
al
weiner
et
al
novel
approach
prevent
treatment
rotavirusinduc
diarrhea
develop
reduc
medic
econom
burden
develop
develop
countri
one
isol
vhh
name
also
refer
shown
broadli
crossreact
differ
human
rotaviru
serotyp
provid
protect
mous
pup
model
rotaviru
infect
aladin
et
al
van
der
vaart
et
al
import
oral
administr
safe
effect
reduc
sever
diarrhea
children
phase
ii
therapeut
clinic
trial
conduct
bangladesh
sarker
et
al
base
studi
modifi
lactobacilli
produc
surfac
anchor
vhh
antibodi
fragment
direct
rotaviru
construct
shown
bind
rotaviru
protect
rotavirusinduc
diarrhea
mous
pup
martin
et
al
pant
et
al
pant
et
al
fragment
also
express
high
level
rice
use
rnai
technolog
suppress
product
major
rice
endogen
storag
protein
tokuhara
et
al
appli
oral
rice
powder
rice
water
simpli
dissolv
rice
powder
water
clostridium
difficil
sporeform
anaerob
bacterium
lead
caus
antibioticassoci
diarrhea
hospit
longterm
care
facil
redel
et
al
primari
treatment
regim
cl
difficil
infect
discontinu
instig
antibiot
administr
vancomycin
metronidazol
patient
experi
relaps
antibiot
therapi
halt
furthermor
incid
sever
cl
difficil
infect
increas
markedli
past
decad
part
emerg
unusu
virul
antibioticresist
strain
redel
et
al
main
strategi
passiv
immun
cl
difficil
base
antibodi
neutral
two
toxin
respons
disrupt
colon
epitheli
tight
junction
babcock
et
al
cloud
kelli
marozsan
et
al
salcedo
et
al
wilcox
two
human
mab
direct
receptorbind
domain
toxin
mab
actoxumab
toxin
b
mab
bezlotoxumab
shown
neutral
cytotox
effect
either
prevent
cl
difficileinduc
mortal
hamster
model
babcock
et
al
phase
ii
human
trial
singl
infus
two
mab
adjunct
treatment
either
vancomycin
metronidazol
highli
success
reduc
rate
recurr
infect
lowi
et
al
two
mab
licens
merck
test
phase
iii
studi
toxin
could
conceiv
neutral
within
lower
gastrointestin
tract
therebi
prevent
critic
first
step
cl
difficileassoci
diseas
pathogenesi
oral
administr
chicken
igi
bovin
antibodi
direct
toxin
b
protect
hamster
model
infect
kelli
et
al
kink
william
lyerli
et
al
robert
et
al
target
cl
difficil
virul
factor
involv
adher
flagellar
cap
protein
flid
may
also
effect
prevent
cl
difficil
infect
mulvey
et
al
limit
report
cl
difficileassoci
diarrhea
therapi
oral
deliv
antibodi
human
warni
et
al
bovin
antibodyenrich
whey
prepar
cow
milk
direct
cl
difficil
toxin
whole
cell
shown
prevent
relaps
standard
antibiot
therapi
safe
well
toler
van
dissel
et
al
numan
et
al
young
et
al
limit
evid
oral
immunotherapi
clinic
set
like
hamper
high
ig
dose
requir
associ
cost
altern
neutral
singledomain
antibodi
deriv
llama
current
develop
toxin
b
hussack
et
al
furthermor
lactobacillu
produc
surfaceanchor
vhh
fragment
toxin
b
delay
death
hamster
challeng
spore
toxin
adelet
cl
difficil
strain
andersen
et
al
submit
diarrheagen
e
coli
classifi
five
welldescrib
group
base
distinct
virul
characterist
clinic
diseas
phylogenet
profil
among
enterohemorrhag
e
coli
ehec
strain
associ
hemorrhag
coliti
hemolyticurem
syndrom
human
enteropathogen
e
coli
epec
strain
caus
diarrhea
children
enterotoxigen
e
coli
etec
strain
associ
travel
diarrhea
caus
diarrhea
least
death
annual
preschool
children
develop
countri
brunser
et
al
buchholz
et
al
svennerholm
lundgren
wherea
etec
ehec
character
product
distinct
toxin
hallmark
phenotyp
epec
abil
produc
attach
effac
ae
lesion
mani
antibiot
use
treat
epec
etec
treatment
option
threaten
rise
multipl
antibioticresist
strain
bacteria
horn
et
al
fact
secretori
ig
breast
milk
protect
neonat
young
infant
diarrhea
import
consid
test
passiv
immunotherapi
manag
infect
loureiro
et
al
intraperiton
inject
mab
shiga
toxin
reduc
system
complic
prolong
surviv
mice
gnotobiot
pig
intestin
infect
e
coli
ehec
krautzpeterson
et
al
mukherje
et
al
sheoran
et
al
oral
administr
igi
reduc
mortal
mice
infect
intestin
ehec
neri
et
al
addit
ig
prepar
cow
chicken
immun
epec
etec
ehec
effect
prophylaxi
infect
farm
anim
ikemori
et
al
marquardt
et
al
rabinovitz
et
al
supplement
bovin
milkderiv
antibodi
prepar
infant
feed
formula
success
use
treat
activ
epec
diseas
infant
one
earliest
control
studi
use
antibodi
mieten
et
al
addit
hyperimmun
bovin
milk
antibodi
product
specif
activ
purifi
colon
factor
antigen
cfa
protect
volunt
challeng
etec
freedman
et
al
contrari
oral
administr
bovin
ig
milk
concentr
bic
cow
hyperimmun
etec
epec
strain
gave
signific
therapeut
benefit
random
placebocontrol
studi
children
e
coliinduc
diarrhea
bangladesh
casswal
et
al
could
differ
specif
antibodi
prepar
better
approach
might
thu
gener
antibodi
specif
virul
factor
accord
estim
world
health
organ
joint
unit
nation
programm
hivacquir
immunodefici
syndrom
million
peopl
live
infect
end
transmiss
women
occur
mucos
surfac
endocervix
cervix
vagina
unprotect
vagin
intercours
chancey
et
al
shattock
moor
despit
extraordinari
genet
divers
viru
broadli
neutral
mab
isol
patient
defin
conserv
epitop
hiv
env
hoxi
walker
burton
wu
et
al
extens
studi
mab
recogn
membran
proxim
extern
region
mper
target
carbohydratespecif
epitop
outer
domain
direct
bind
site
walker
burton
wu
et
al
potent
mab
isol
target
neutral
panel
wu
et
al
passiv
intraven
transfer
human
neutral
mab
target
provid
dosedepend
protect
macaqu
vagin
challeng
strain
shiv
suggest
antibodi
may
diffus
mucos
submucos
layer
hessel
et
al
hessel
et
al
mascola
et
al
moldt
et
al
parren
et
al
tabl
furthermor
vagin
administ
protect
mucos
shiv
challeng
anim
model
suggest
use
antibodi
potenti
vagin
microbicid
veazey
et
al
veselinov
et
al
human
infus
neutral
mab
reduc
viral
rebound
individu
trkola
et
al
three
mab
assess
gelformul
microbicid
phase
clinic
trial
high
concentr
neutral
mab
show
promis
microbicid
formul
prohibit
expens
produc
amount
requir
consequ
antihivneutr
antibodi
express
high
level
plant
excel
result
obtain
term
product
neutral
activ
marus
et
al
rademach
et
al
ramessar
et
al
human
mab
ibalizumab
formerli
taidm
biolog
taiwan
pro
progen
pharmaceut
new
york
target
receptor
respect
shown
promis
result
earli
clinic
trial
given
intraven
infus
bruno
jacobson
jacobson
et
al
antibodi
might
use
mixtur
antibodi
target
viru
microbicid
formul
camelida
heavi
chain
antibodi
fragment
react
neutral
varieti
strain
also
isol
forsman
et
al
jahnichen
et
al
mccoy
et
al
lead
vhh
candid
neutral
strain
variou
clade
show
broadli
neutral
vhh
gener
immun
mccoy
et
al
camelida
heavi
chain
antibodi
high
potenti
microbicid
applic
low
product
cost
high
stabil
favor
releas
vagin
ring
devic
tissu
penetr
properti
gorlani
et
al
lactobacilli
found
colonyform
unit
cfu
ml
vagin
fluid
cfu
per
singl
vagin
epitheli
cell
thu
suggest
vector
deliveri
antibodi
fragment
microbicid
genit
tract
chancey
et
al
lagenaur
et
al
liu
et
al
inde
scfv
produc
lactobacilli
reduc
transmiss
cellassoci
hiv
vitro
hupblscid
mous
model
chancey
et
al
chronic
vulvovagin
candidiasi
sever
affect
qualiti
life
million
women
world
frequent
refractori
antifung
treatment
sobel
virul
factor
albican
includ
mannoprotein
favor
fungal
adher
well
aspartyl
proteinas
sap
crucial
role
acquisit
nutrient
invas
destruct
host
tissu
barrier
de
bernardi
et
al
intravagin
administr
mab
human
singledomain
antibodi
vh
chain
recogn
mannoprotein
secretori
aspartyl
albican
confer
protect
vagin
challeng
cabeza
et
al
debernardi
et
al
de
bernardi
et
al
monoclon
antibodi
target
major
cell
wall
compon
inhibit
hyphal
growth
adher
human
epitheli
cell
vitro
confer
signific
protect
albican
vagin
rat
model
albican
infect
capodicasa
et
al
torosantucci
et
al
torosantucci
et
al
develop
antiidiotyp
antibodi
yeast
killer
toxin
kt
activ
open
new
avenu
therapeut
applic
casson
magliani
et
al
monoclon
ab
scfv
fragment
carri
intern
imag
activ
domain
kt
produc
pichia
anomala
elicit
idiotyp
vaccin
rat
ktneutral
mous
mab
polonelli
et
al
yeast
killer
toxin
antiidiotyp
monoclon
mab
scfv
antibodi
abl
exert
direct
candidacid
activ
vitro
rat
vagin
model
furthermor
engin
streptococcu
gordonii
strain
produc
colon
mucos
surfac
inocul
intravagin
rat
exert
therapeut
effect
albican
vagin
infect
beninati
et
al
sinc
ehrlich
recognit
potenti
antibodi
therapeut
agent
earli
twentieth
centuri
antibodi
gain
import
treatment
varieti
diseas
today
passiv
antibodi
administr
use
treat
prevent
diseas
caus
hepat
b
viru
rabi
viru
rsv
cl
tetani
cl
botulinum
vaccinia
viru
echoviru
enteroviru
casadeval
et
al
administr
hors
antitoxin
remain
specif
therapi
avail
botul
antibodi
administ
human
anim
plasma
serum
pool
human
ig
intraven
ivig
intramuscular
imig
subcutan
scig
use
hightit
human
ivig
imig
immun
convalesc
donor
mab
patient
pad
prophylact
replac
therapi
scig
intraven
imig
method
choic
prevent
infect
antibodi
therapi
hiv
rotaviru
influenza
bacillu
anthraci
cryptococcu
neoforman
cl
difficil
str
mutan
ps
aeruginosa
albican
clinic
develop
antibodi
variou
microorgan
includ
h
pylori
e
coli
research
develop
renew
interest
antibodybas
therapi
consequ
major
advanc
technolog
antibodi
product
combin
need
new
therapeut
agent
emerg
diseas
ebola
sever
acut
respiratori
syndrom
bird
flu
west
nile
viru
bioterror
agent
new
antibioticresist
microorgan
staphylococcu
aureu
e
coli
enterococci
cl
difficil
howev
although
antibodi
proven
good
antimicrobi
agent
one
mab
palivizumab
licens
infecti
diseas
rsv
infect
hope
advanc
genom
proteom
result
improv
knowledg
regard
molecular
mechan
pathogen
possibl
gener
fulli
human
antibodi
transgen
human
mice
perhap
near
futur
transgen
human
cow
well
new
develop
phage
librari
technolog
acceler
develop
antibodi
product
furthermor
product
antibodi
lower
cost
use
transgen
plant
transgen
cow
well
situ
deliveri
antibodi
fragment
recombin
bacteria
lead
new
applic
antibodi
therapeut
infecti
diseas
mucos
deliveri
antibodi
engin
differ
format
fuse
antimicrobi
result
increas
potenc
new
molecular
method
render
nonimmunogen
new
develop
contribut
realiz
erhlich
dream
magic
bullet
